Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-104: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs ODM 104 (Primary) ; Entacapone; Levodopa/carbidopa
- Indications Parkinsonian disorders
- Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics
- Acronyms NOCIFIM
- Sponsors Orion
- 31 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 06 May 2013 New trial record